[{"id":"79649cc6-d582-4cf7-94a7-6b84b6103cab","acronym":"","url":"https://clinicaltrials.gov/study/NCT04901702","created_at":"2021-05-25T18:52:49.387Z","updated_at":"2025-02-25T12:28:07.986Z","phase":"Phase 1/2","brief_title":"Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma","source_id_and_acronym":"NCT04901702","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" EWSR1 • FLI1","pipe":"","alterations":" ","tags":["EWSR1 • FLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Talzenna (talazoparib) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 06/09/2021","start_date":" 06/09/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"f7e6df94-a121-41c2-ab20-30322990863a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05327010","created_at":"2022-04-14T12:53:52.597Z","updated_at":"2025-02-25T14:02:49.505Z","phase":"Phase 2","brief_title":"Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial","source_id_and_acronym":"NCT05327010","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRCA1 • BRCA2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • BARD1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12 • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["KRAS • BRCA1 • BRCA2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • BARD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12 • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 11/14/2022","start_date":" 11/14/2022","primary_txt":" Primary completion: 08/04/2025","primary_completion_date":" 08/04/2025","study_txt":" Completion: 08/04/2025","study_completion_date":" 08/04/2025","last_update_posted":"2025-02-19"},{"id":"527306d6-34b9-4ad0-b5f6-cf22600b56c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03968406","created_at":"2024-02-22T16:25:39.444Z","updated_at":"2025-02-25T15:11:11.864Z","phase":"Phase 1","brief_title":"Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers","source_id_and_acronym":"NCT03968406","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RAD51","pipe":"","alterations":" ","tags":["RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 09/26/2019","start_date":" 09/26/2019","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-02-13"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"4cabb472-72d9-4aab-84c5-57e99ca09609","acronym":"SWOG S1929","url":"https://clinicaltrials.gov/study/NCT04334941","created_at":"2021-01-18T20:59:20.159Z","updated_at":"2025-02-25T16:37:48.646Z","phase":"Phase 2","brief_title":"Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker","source_id_and_acronym":"NCT04334941 - SWOG S1929","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SLFN11","pipe":"","alterations":" ","tags":["SLFN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Talzenna (talazoparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 07/20/2020","start_date":" 07/20/2020","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2025-02-06"},{"id":"d8a6d977-6f13-416a-b8b4-9b7236d1ef6b","acronym":"TAPUR","url":"https://clinicaltrials.gov/study/NCT02693535","created_at":"2021-01-17T17:24:20.327Z","updated_at":"2025-02-25T14:00:57.498Z","phase":"Phase 2","brief_title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","source_id_and_acronym":"NCT02693535 - TAPUR","lead_sponsor":"American Society of Clinical Oncology","biomarkers":" BRAF","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • temsirolimus • letrozole • axitinib • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 3791","initiation":"Initiation: 03/14/2016","start_date":" 03/14/2016","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-01-29"},{"id":"7eca0fb2-04d0-4d7b-817d-419169892d08","acronym":"","url":"https://clinicaltrials.gov/study/NCT06735742","created_at":"2025-02-26T09:24:12.626Z","updated_at":"2025-02-26T09:24:12.626Z","phase":"","brief_title":"A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer","source_id_and_acronym":"NCT06735742","lead_sponsor":"Pfizer","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 01/31/2025","start_date":" 01/31/2025","primary_txt":" Primary completion: 07/25/2031","primary_completion_date":" 07/25/2031","study_txt":" Completion: 07/25/2031","study_completion_date":" 07/25/2031","last_update_posted":"2024-12-16"},{"id":"d11a0654-6c29-4ed7-bc6d-989164139e3c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06733337","created_at":"2025-02-26T09:56:43.195Z","updated_at":"2025-02-26T09:56:43.195Z","phase":"","brief_title":"A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.","source_id_and_acronym":"NCT06733337","lead_sponsor":"Pfizer","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 01/31/2025","start_date":" 01/31/2025","primary_txt":" Primary completion: 06/22/2029","primary_completion_date":" 06/22/2029","study_txt":" Completion: 06/22/2029","study_completion_date":" 06/22/2029","last_update_posted":"2024-12-13"},{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"6c1bf2f9-a643-4b80-84fa-1e32b26a8869","acronym":"BTCRC-BRE18-337","url":"https://clinicaltrials.gov/study/NCT03911973","created_at":"2021-01-18T19:15:11.647Z","updated_at":"2024-07-02T16:34:37.336Z","phase":"Phase 1/2","brief_title":"Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers","source_id_and_acronym":"NCT03911973 - BTCRC-BRE18-337","lead_sponsor":"Kari Wisinski","biomarkers":" HER-2 • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 negative • BRCA1 negative","tags":["HER-2 • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • BRCA1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • gedatolisib (PF-05212384)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 04/17/2019","start_date":" 04/17/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-07"},{"id":"b28a300d-a648-41cb-b9b3-e37a6c33dd25","acronym":"LUNG-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT04173507","created_at":"2021-01-18T20:21:36.422Z","updated_at":"2024-07-02T16:34:59.352Z","phase":"Phase 2","brief_title":"Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)","source_id_and_acronym":"NCT04173507 - LUNG-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" STK11","pipe":" | ","alterations":" STK11 mutation","tags":["STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • Talzenna (talazoparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 02/14/2020","start_date":" 02/14/2020","primary_txt":" Primary completion: 11/24/2021","primary_completion_date":" 11/24/2021","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-04"},{"id":"ef2ab7b8-a2e5-4df2-83fe-3e4e96f58f67","acronym":"","url":"https://clinicaltrials.gov/study/NCT04693468","created_at":"2021-01-19T20:49:06.628Z","updated_at":"2024-07-02T16:34:58.952Z","phase":"Phase 1","brief_title":"Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial","source_id_and_acronym":"NCT04693468","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ALK • MET • BRCA1 • BRCA2 • ROS1 • RAD51C • RAD51D","pipe":" | ","alterations":" MET amplification • MET mutation • MET expression • ALK translocation","tags":["ALK • MET • BRCA1 • BRCA2 • ROS1 • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET mutation • MET expression • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Ibrance (palbociclib) • Talzenna (talazoparib) • axitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 09/03/2025","primary_completion_date":" 09/03/2025","study_txt":" Completion: 09/03/2025","study_completion_date":" 09/03/2025","last_update_posted":"2024-06-04"},{"id":"80d058fa-b19a-4e22-b59d-ca59b8425b25","acronym":"","url":"https://clinicaltrials.gov/study/NCT04991480","created_at":"2021-08-05T13:53:03.393Z","updated_at":"2024-07-02T16:34:59.371Z","phase":"Phase 1","brief_title":"A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04991480","lead_sponsor":"Artios Pharma Ltd","biomarkers":" HER-2 • BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 negative","tags":["HER-2 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • Zejula (niraparib) • ART4215"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 390","initiation":"Initiation: 09/13/2021","start_date":" 09/13/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-06-03"},{"id":"e381b221-6768-4bcf-80c5-d9caedaede97","acronym":"","url":"https://clinicaltrials.gov/study/NCT05898399","created_at":"2023-06-12T16:09:01.959Z","updated_at":"2024-07-02T16:35:01.189Z","phase":"Phase 1/2","brief_title":"Study of ART6043 in Advanced/Metastatic Solid Tumors Patients","source_id_and_acronym":"NCT05898399","lead_sponsor":"Artios Pharma Ltd","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Talzenna (talazoparib) • Zejula (niraparib) • ART6043"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 06/30/2023","start_date":" 06/30/2023","primary_txt":" Primary completion: 05/14/2026","primary_completion_date":" 05/14/2026","study_txt":" Completion: 12/14/2026","study_completion_date":" 12/14/2026","last_update_posted":"2024-05-24"},{"id":"77c55f6e-4ff7-43d4-a607-9955ade8f607","acronym":"","url":"https://clinicaltrials.gov/study/NCT05035745","created_at":"2021-09-05T15:55:43.795Z","updated_at":"2024-07-02T16:35:02.873Z","phase":"Phase 1/2","brief_title":"Selinexor \u0026 Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)","source_id_and_acronym":"NCT05035745","lead_sponsor":"National University Hospital, Singapore","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-05-17"},{"id":"88461e0e-9239-461f-831e-38bf1a8c7c20","acronym":"","url":"https://clinicaltrials.gov/study/NCT04207190","created_at":"2021-01-18T20:29:32.215Z","updated_at":"2024-07-02T16:35:05.019Z","phase":"Phase 1","brief_title":"Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04207190","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 10/23/2020","start_date":" 10/23/2020","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-05-08"},{"id":"c67606ea-7796-46a1-9d35-f3d0edacc3ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT02912572","created_at":"2021-01-18T14:17:54.432Z","updated_at":"2024-07-02T16:35:08.730Z","phase":"Phase 2","brief_title":"Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer","source_id_and_acronym":"NCT02912572","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MSI • POLE • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • POLE mutation • MSH6 expression","tags":["MSI • POLE • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • POLE mutation • MSH6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • Talzenna (talazoparib) • axitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 11/14/2016","start_date":" 11/14/2016","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-04-19"},{"id":"d1d92135-3942-4614-a45f-c926f258d765","acronym":"","url":"https://clinicaltrials.gov/study/NCT02286687","created_at":"2021-01-18T10:46:38.075Z","updated_at":"2024-07-02T16:35:11.145Z","phase":"Phase 2","brief_title":"Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes","source_id_and_acronym":"NCT02286687","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • PTEN • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA2 deletion • BRCA1 deletion • BRCA mutation • BRCA deletion","tags":["BRCA1 • BRCA2 • PTEN • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA2 deletion • BRCA1 deletion • BRCA mutation • BRCA deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 12/22/2014","start_date":" 12/22/2014","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-04-05"},{"id":"c284c9a8-e24e-458d-9f79-e38507128672","acronym":"","url":"https://clinicaltrials.gov/study/NCT04039230","created_at":"2021-01-18T19:48:59.137Z","updated_at":"2024-07-02T16:35:12.082Z","phase":"Phase 1/2","brief_title":"Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.","source_id_and_acronym":"NCT04039230","lead_sponsor":"Massachusetts General Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 10/09/2019","start_date":" 10/09/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-04-01"},{"id":"f73911e5-e1de-4e1b-ac56-12e2040f406e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04134884","created_at":"2021-01-18T20:11:32.856Z","updated_at":"2024-07-02T16:35:13.096Z","phase":"Phase 1","brief_title":"Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer","source_id_and_acronym":"NCT04134884","lead_sponsor":"Kathy Miller","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 04/01/2020","start_date":" 04/01/2020","primary_txt":" Primary completion: 01/30/2024","primary_completion_date":" 01/30/2024","study_txt":" Completion: 03/14/2024","study_completion_date":" 03/14/2024","last_update_posted":"2024-03-22"},{"id":"d460cb48-700b-4991-84e5-f141a6a20718","acronym":"","url":"https://clinicaltrials.gov/study/NCT03990896","created_at":"2021-01-18T19:37:18.270Z","updated_at":"2024-07-02T16:35:13.950Z","phase":"Phase 2","brief_title":"Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial","source_id_and_acronym":"NCT03990896","lead_sponsor":"Massachusetts General Hospital","biomarkers":" HER-2 • BRCA1 • BRCA","pipe":" | ","alterations":" BRCA1 mutation • HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation • PTEN mutation + HR positive","tags":["HER-2 • BRCA1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/18/2021","start_date":" 11/18/2021","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-19"},{"id":"1bada8c3-f2f1-4030-ad23-c27e1828e629","acronym":"","url":"https://clinicaltrials.gov/study/NCT04550494","created_at":"2021-01-18T21:45:36.970Z","updated_at":"2024-07-02T16:35:16.133Z","phase":"Phase 2","brief_title":"Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations","source_id_and_acronym":"NCT04550494","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • BAP1 • CDK12 • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • RAD54L • FANCF • FANCL • FANCI • FANCM • BACH1 • FANCD2 • FANCE • FANCG • FANCB • FANCC","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation","tags":["BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • BAP1 • CDK12 • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • RAD54L • FANCF • FANCL • FANCI • FANCM • BACH1 • FANCD2 • FANCE • FANCG • FANCB • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/26/2021","start_date":" 04/26/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-06"},{"id":"17629d29-f29f-4b1f-9200-4c60a23cc92d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05141708","created_at":"2021-12-02T18:54:31.206Z","updated_at":"2024-07-02T16:35:19.002Z","phase":"","brief_title":"Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m","source_id_and_acronym":"NCT05141708","lead_sponsor":"Pfizer","biomarkers":" HER-2 • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • HER-2 negative • BRCA mutation","tags":["HER-2 • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • HER-2 negative • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 12/17/2021","start_date":" 12/17/2021","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2024-02-16"},{"id":"d1050dd4-c498-4a7c-ac54-2e29de5677e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04987931","created_at":"2021-08-03T18:52:58.572Z","updated_at":"2024-07-02T16:35:22.805Z","phase":"","brief_title":"Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT04987931","lead_sponsor":"Pfizer","biomarkers":" HER-2 • BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 negative","tags":["HER-2 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib)"],"overall_status":"Completed","enrollment":" Enrollment 84","initiation":"Initiation: 08/20/2021","start_date":" 08/20/2021","primary_txt":" Primary completion: 10/11/2021","primary_completion_date":" 10/11/2021","study_txt":" Completion: 10/11/2021","study_completion_date":" 10/11/2021","last_update_posted":"2024-01-22"}]